옵션 체인은 다양한 행사가격과 만기일에 대한 CEL-SCI의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 CEL-SCI에 대한 시장 심리를 평가합니다..

CEL-SCI (AMEX:CVM) 주식, 옵션 체인

CEL-SCI

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

News

Pre-Market Outlook

Markets

Trading Ideas

$LUNA

CCTG

CTXR

LUNA

월요일(30일) 아침 미국 주식 선물이 하락한 가운데, 오늘 투자자들의 관심을 끌 수 있는 종목은 다음과 같다. 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 파마슈티컬스 및 지니어스 그룹

월요일 주목해야 할 주식: 셀 사이, CCSC 테크놀로지, 루나 이노베이션스, 시티우스 및 지니어스 그룹

CEL-SCI Corp

Morgan Stanley ETF Trust Calvert US Mid-Cap Core Responsible Index ETF

Sila Realty Trust Inc Ordinary Shares - Class A

Sila Realty Trust Inc Ordinary Shares - Class T

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 65.2% to $2.71 during Monday's pre-market session. The market value of their outstanding shares is at $11.3 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock moved upwards by 57.47% to $0.31. The market value of their outstanding shares is at $10.2 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares rose 42.43% to $0.53. The company's market cap stands at $29.1 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares rose 39.39% to $4.6. The market value of their outstanding shares is at $8.1 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares moved upwards by 17.64% to $1.8. The company's market cap stands at $7.5 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock rose 15.29% to $0.63. The market value of their outstanding shares is at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) shares declined by 40.0% to $8.06 during Monday's pre-market session. The company's market cap stands at $24.3 million. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock decreased by 29.97% to $0.42. The company's market cap stands at $26.8 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 13.64% to $0.38. The company's market cap stands at $27.4 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 12.48% to $3.93. The company's market cap stands at $203.6 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) stock fell 10.66% to $0.53. The company's market cap stands at $314.9 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock declined by 9.91% to $0.19. The market value of their outstanding shares is at $3.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

CPHI

MRNS

OTRK

PLRZ

QNRX

SENS

TRAW

VINC

XAIR

12 Health Care Stocks Moving In Monday's Pre-Market Session

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 0.7% on Monday.
The Dow traded down 0.67% to 42,702.02 while the NASDAQ fell 0.73% to 19,578.50. The S&amp;P 500 also fell, dropping, 0.72% to 5,928.08.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares rose by 0.2% on Monday.
In trading on Monday, consumer discretionary shares dipped by 1.2%.
Top Headline
U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 5% to $6.69. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 12% to $9.27. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 7% to $14.48. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vertical Aerospace Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTL#NYSE">EVTL</a>) shares dropped 15% to $13.20. The company recently announced it has finalized an investment agreement for up to $50 million in new funding.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 41% to $7.92. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 31% to $0.42. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1.1% to $71.34 while gold traded down 0.6% at $2,616.00.
Silver traded down 2% to $29.385 on Monday, while copper fell 0.8% to $4.0880.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.46%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.57%. Spain's IBEX 35 Index rose 0.05%, while London's FTSE 100 fell 0.35%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
<li>The Dallas Fed&#8217;s Texas manufacturing activity index rose six points to a reading of 3.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Eurozone

Commodities

Intraday Update

CTKB

EVTL

HSAI

Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 100 points on Monday.
The Dow traded down 0.61% to 42,725.52 while the NASDAQ fell 0.58% to 19,608.47. The S&amp;P 500 also fell, dropping, 0.59% to 5,935.35.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares fell by just 0.6% on Monday.
In trading on Monday, consumer discretionary shares dipped by 2.2%.
Top Headline
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 6% to $6.79. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 13% to $9.36. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 9% to $14.69. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) shares dropped 20% to $56.60.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 39% to $8.25. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 28% to $0.4301. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $71.32 while gold traded down 0.6% at $2,615.80.
Silver traded down 1.5% to $29.505 on Monday, while copper fell 0.7% to $4.0930.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.65%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.58%. Spain's IBEX 35 Index rose 0.01%, while London's FTSE 100 fell 0.62%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Earnings

Equities

QMCO

Crude Oil Gains 1%; Chicago PMI Falls In December

WIIM

Cel-Sci shares are trading lower after the company announced a $5 million public offering of 16.13 million shares.

U.S. stocks traded lower this morning, with the Dow Jones dipping around 600 points on Monday.
Following the market opening Monday, the Dow traded down 1.40% to 42,390.68 while the NASDAQ fell 1.53% to 19,419.90. The S&amp;P 500 also fell, dropping, 1.43% to 5,885.51.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares fell by just 0.3% on Monday.
In trading on Monday, consumer discretionary shares dipped by 2.1%.
Top Headline
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Intrusion Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) shares shot up 192% to $6.34.</li>
<li>Shares of Nxu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>)got a boost, surging 210% to $0.7556.</li>
<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) shares were also up, gaining 186% to $1.1600.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Abpro Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) shares dropped 40% to $2.71.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 39% to $8.15. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 35% to $0.3923. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 0.9% to $71.24 while gold traded down 0.4% at $2,622.40.
Silver traded down 1% to $29.680 on Monday, while copper fell 0.6% to $4.0985.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX fell 0.4% and France's CAC 40 fell 0.5%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.6%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

INTZ

WATT

US Stocks Open Lower; Dow Tumbles 600 Points

Cel-Sci Corporation (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) shares are trading lower premarket on Monday.
On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42716897/cel-sci-announces-pricing-of-5-million-public-offering" rel="noreferrer noopener">warrants at $0.31 per share</a>.
The company aims to raise around $5 million in gross proceeds. The offering is expected to close on December 31, 2024, subject to customary conditions.
The company plans to use proceeds to support the development of Multikine, general <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42711737/cel-sci-announces-proposed-public-offering-of-common-stock" rel="noreferrer noopener">corporate purposes, and working capital</a>.
Earlier this month, CEL-SCI emphasized the strong biological rationale for using Multikine in its FDA-approved confirmatory registration study for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42461679/cel-sci-highlights-biological-rationale-for-the-use-of-multikine-in-the-confirmatory-registration-" rel="noreferrer noopener">head and neck cancer</a>.
The study, involving 212 newly diagnosed patients with locally advanced, resectable head and neck cancer, will focus on those who demonstrated a 73% survival rate with Multikine compared to 45% for control patients in the prior Phase 3 trial.
Price Action: CVM shares are down 29.9% at $0.4204 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42719119/us-stock-futures-slip-after-fridays-fall-santa-rally-in-doubt-analyst-calls-it-a-bit-of-profit-taking" target="_blank" rel="noreferrer noopener">US Stock Futures Slip After Friday&#8217;s Fall: &#8216;Santa Rally&#8217; In Doubt? Analyst Calls It A Bit Of Profit-Taking</a></li>
</ul>
Photo via Shutterstock.

Offerings

Small Cap

What's Going On With Cel-Sci Shares Premarket On Monday?

U.S. stock futures declined on Monday after ending <a href="https://www.benzinga.com/24/12/42711387/wall-streets-santa-rally-at-risk-palantir-dethrones-nvidia-consumer-confidence-pulls-back-this-week-in-the-markets">lower </a>on Friday. All four index futures slipped in trade.
Although ‘Santa Rally' has not picked up pace despite rising over 1% on Christmas Eve, the S&amp;P 500 index is on its way to registering a robust 20% plus return for the second consecutive year in 2024.
The 10-year and two-year Treasury notes yielded 4.59% and 4.30%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025, FOMC meeting was at 88.8%, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.18%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.21%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.21%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.02%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was down 0.23% to $593.66 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.20% to $521.43, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
U.S. stock markets experienced a <a href="https://www.benzinga.com/news/earnings/24/12/42717902/dow-dips-over-300-points-but-records-weekly-gain-greed-index-remains-in-fear-zone">lower</a> close on Friday as major indices retreated following gains on a weekly basis. The Dow Jones Industrial Average declined by over 300 points, while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) suffered losses.
The Dow Jones Industrial Average closed at 42,992.21, down approximately 0.77%, whereas, the S&amp;P 500 and Nasdaq Composite also experienced declines, falling by 1.11% and 1.49%, respectively.
All sectors within the S&amp;P 500 ended the day in negative territory. Consumer discretionary, communication services, and information technology sectors recorded the most significant losses.
On the economic front, U.S. wholesale inventories decreased by 0.2% in November. The U.S. trade deficit in goods widened to $102.86 billion.
Despite Friday&#8217;s losses, major indices still recorded positive returns for the week. The Dow Jones gained approximately 0.4%, ending a three-week losing streak. The S&amp;P 500 added 0.7%, and the Nasdaq rose by about 0.8%.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.49%</td>
<td>19,722.03</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.11%</td>
<td>5.970.84</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.77%</td>
<td>42,992.21</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.56%</td>
<td>2,244.59</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
Chamath Palihapitiya, the billionaire investor, and former Facebook executive, explained in an X post that greater concentration in a few stocks increases the risks of investing.
He highlighted the inequality in the weight of the stocks within the S&amp;P 500 index and said, "If there is any market volatility, the lack of diversification could cause massive impairment."
Kevin Gordon, the director and senior investment strategist at Charles Schwab shared a graphic showing the top ten stocks in the S&amp;P 500 represent 40% of the index market capitalization.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This needs to be fixed or it will end in disaster. Why? Average Americans buy S&amp;P 500 index ETFs, in part, because Buffett told them to. They were told they would pay very little and get diversification in the 500 best companies on earth to ride out storms. But as… <a href="https://t.co/YEYhjvrSg7">https://t.co/YEYhjvrSg7</a>
&mdash; Chamath Palihapitiya (@chamath) <a href="https://twitter.com/chamath/status/1873144394100187263?ref_src=twsrc%5Etfw">December 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
As the ‘Magnificent Seven&#8217; stock led the market lower on Friday, Louis Navellier of Navellier &amp; Associates in his note said, "The Santa Claus rally is in serious doubt now." But he quipped that "It certainly appears to be a bit of profit-taking."
Reinstalling confidence among investors Navellier added that Friday's selloff should not be worrisome and the ‘B team' of traders were getting rid of their inventory before the weekend.
"Investors shouldn&#8217;t worry about the sell-off – it&#8217;s just what we call inventory cleaning. But there is a sell-off today, and if you did want to buy, it's not a bad time to nibble. Normally, we rally going into New Year&#8217;s, and we normally rally in the new year. So, if we don&#8217;t, it means we have to wait until the A team comes back, which will of course be after the New Year&#8217;s holiday," he added.
The 10-year Treasury yield hit 4.631% during Friday's session, which was its highest level since May 30, 2024. However, it is currently yielding 4.59% on Monday.
Talking about the spiking yields, Ed Yardeni, the president at Yardeni Research said in a note "The Bond Vigilantes are sending a loud warning message. They aren&#8217;t convinced Donald Trump, the new sheriff coming to town, will maintain fiscal law and order any better than the old sheriff. They are also losing their confidence in Jerome Powell, the deputy in charge of monetary law and order."
According to Navellier, "The bond vigilantes have been pushing the narrative that the Trump tariffs are going to be inflationary, but the reality is that a strong U.S. dollar causes the prices of commodities and imported goods to decline."
Yardeni, in his note, mentioned that a pullback in the markets may have already started. "We still think that the 10-year yield should trade around 4.50% plus/minus 25bps in 2025. But we can&#8217;t rule out a move back up to last year&#8217;s high of 5.00% early next year. That&#8217;s another reason why we expect a stock market pullback/correction that might have started already. The S&amp;P 500 peaked at a record 6090.27 on Dec. 6," he said.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
A few important data points will be released in this truncated week that will help investors determine the future course of action.
<ul>
<li>On Monday, Chicago Business Barometer (PMI) data for December will announced at 9:45 a.m., ET.</li>
</ul>
<ul>
<li>November's pending home sales data will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Tuesday, November's S&amp;P Case-Shiller home price index for 20 cities will be announced at 9:00 a.m., ET.</li>
</ul>
<ul>
<li>No data is slated to be released on Wednesday, Jan. 1, owning to a New Year's holiday.</li>
</ul>
<ul>
<li>On Thursday, initial jobless claims till Dec. 28 will be announced at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>Construction spending data for November will be released at 10:00 a.m., ET.</li>
</ul>
<ul>
<li>On Friday, ISM manufacturing data for December will be announced at 10:00 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down 43.34% in premarket trade after it priced its $5 million public offering of 16.13 million common shares at 31 cents per share.</li>
</ul>
<ul>
<li>CCSC Technology International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) was up 31.71% after its earnings on Friday. Its revenue surged by 22.9% year-over-year to $9.2 million for the third quarter.</li>
</ul>
<ul>
<li>Citius Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) was down 16.58% after reporting a net loss of $39.4 million, or $5.97 per share for the full year ended Sept. 30, versus a year-ago net loss of $32.5 million, or $5.57 per share.</li>
</ul>
<ul>
<li>Genius Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) was up 15.81% in premarket after posting first-half revenue of $4.9 million, down from $11.8 million in the year-ago period. Its net assets surged 177% to $54.6 million from $19.7 million as of Dec. 31, 2023.</li>
</ul>
<ul>
<li>Intrusion Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) was up 125.93% in premarket after Dow Newswire reported Streeterville Capital has acquired a 9.8% stake in the company.</li>
</ul>
<ul>
<li>Amplitech Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) was up 24.17% as it raised $5.8 million in gross proceeds for the company before fees and expenses were deducted. It was a direct offer of 1,871,000 shares of common stock at $3.10 per share to institutional investors.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.18% to hover around $70.47 per barrel.
The gold spot index was down by 0.25% to $2,625.56 per ounce. The Dollar Index was down 0.05% to 107.947 level.
Asian markets were mostly lower on Monday as Hong Kong&#8217;s Hang Seng, Japan&#8217;s Nikkei 225, Australia&#8217;s ASX 200, and South Korea&#8217;s Kospi declined. Whereas, China&#8217;s CSI 300 ended higher. European markets were mixed.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678368/sp-500-hits-57-all-time-highs-in-record-breaking-2024-magnificent-7-drive-30-of-nasdaqs-surge">S&amp;P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq&#8217;s Surge</a> </li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Futures

Economics

AMPG

NVDA

TSLA

US Stock Futures Slip After Friday's Fall: 'Santa Rally' In Doubt? Analyst Calls It A Bit Of Profit-Taking

Shares of Vincerx Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) rose sharply in today's pre-market trading after the company announced a binding term sheet for a strategic <a href="https://www.benzinga.com/quote/VINC/news">merger with Oqory, Inc</a>.
Vincerx Pharma shares jumped 63.9% to $0.3180 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Intrusion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) gained 120% to $4.76 in pre-market trading after surging around 380% on Friday.</li>
<li>Rekor Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REKR#NASDAQ">REKR</a>) gained 98.4% to $2.58 in pre-market trading after gaining 27% on Friday.</li>
<li>Energous Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) rose 78.7% to $0.7237 in pre-market trading.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) gained 54.2% to $2.19 in pre-market trading after gaining 3% on Friday. Castellum announced the pricing of a previously announced stock offering of 4,355,000 shares at 85 cents per share for gross proceeds of approximately $3.7 million.</li>
<li>Solidion Technology Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) gained 51.2% to $1.06 in pre-market trading after surging around 69% on Friday.</li>
<li>Aeries Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>) gained 41.4% to $1.24 in pre-market trading after falling around 5% on Friday.</li>
<li>KORE Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) rose 31.6% to $3.21 in pre-market trading after climbing around 28% on Friday.</li>
<li>Palladyne AI Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDYN#NASDAQ">PDYN</a>) gained 22.7% to $14.45 in pre-market trading after gaining over 61% on Friday.</li>
<li>Solid Power, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) gained 15% to $2.45 in pre-market trading after adding 9% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) fell 43.3% to $0.34 in pre-market trading as the company priced its $5 million public offering 16.13 million common shares at 31 cents per share.</li>
<li>Snow Lake Resources Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITM#NASDAQ">LITM</a>) shares tumbled 33.1% to $1.07 in pre-market trading after surging around 82% on Friday.</li>
<li>iLearningEngines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AILE#NASDAQ">AILE</a>) declined 27.5% to $0.43 in pre-market trading after jumping around 267% on Friday.</li>
<li>Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares dipped 16.5% to $3.07 in pre-market trading. Citius Pharmaceuticals reported a net loss of $39.4 million, or $5.97 per share for the full year ended Sept. 30, versus a year-ago net loss of $32.5 million, or $5.57 per share.</li>
<li>Hudson Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSON#NASDAQ">HSON</a>) shares fell 15.5% to $11.31 in pre-market trading.</li>
<li>Tamboran Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBN#NYSE">TBN</a>) fell 14.4% to $16.00 in pre-market trading.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) shares fell 14.4% to $1.97 in pre-market trading after jumping 32% on Friday.</li>
<li>Nature&#8217;s Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) fell 13.4% to $13.01 in today's pre-market trading.</li>
<li>HarborOne Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) dipped 11.5% to $10.60 in pre-market trading.</li>
<li>Sprott Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SII#NYSE">SII</a>) fell 6.4% to $39.31 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42700627/how-to-earn-500-a-month-from-rpm-international-stock-ahead-of-q2-earnings">How To Earn $500 A Month From RPM International Stock Ahead Of Q2 Earnings</a></li>
</ul>

Advanced Environmental Recycling Technologies

AERT

AILE

HONE

HSON

KORE

LITM

NATR

PDYN

REKR

SLDP

Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>CEL-SCI Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) said it priced its $5 million public offering 16.13 million common shares at 31 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. CEL-SCI shares fell 8.6% to $0.55 in the after-hours trading session.</li>
<li>CCSC Technology International Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCTG#NASDAQ">CCTG</a>) posted a net loss of $0.7 million for the six months ended Sept. 30, versus a year-ago net income of $0.4 million. Its revenue surged by 22.9% year-over-year to $9.2 million during the period. CCSC Technology International shares jumped 49.4% to $2.45 in after-hours trading.</li>
<li>Luna Innovations Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNA#NASDAQ">LUNA</a>) announced that Pamela Coe, a member of the Board of Directors, will be retiring from the Luna board. Luna Innovations shares fell 5.5% to $2.05 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Citius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) reported a net loss of $39.4 million, or $5.97 per share for the full year ended Sept. 30, versus a year-ago net loss of $32.5 million, or $5.57 per share. Citius Pharmaceuticals shares slipped 1.9% to $1.0207 in the after-hours trading session.</li>
<li>Genius Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) posted first-half revenue of $4.9 million, down from $11.8 million in the year-ago period. Its net assets surged 177% to $54.6 million from $19.7 million as of Dec. 31, 2023. Genius Group shares jumped 11.6% to $0.72 in the after-hours trading session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42700627/how-to-earn-500-a-month-from-rpm-international-stock-ahead-of-q2-earnings">How To Earn $500 A Month From RPM International Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo courtesy: Shutterstock

CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday

Reported Earlier, CEL-SCI Prices $5M Public Offering 16.13M Common Shares At $0.31/Share

<ul>
<li>Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery</li>
<li>Factors supporting the go-ahead for the 212-person registration study in the target population include:
<ul>
<li>Multikine led to significant rates of tumor regression</li>
<li>Pre-surgical tumor regressions were confirmed at surgery and forecast survival benefit</li>
<li>Target population is likely to show significant survival prolongation in the confirmatory study</li>
</ul>
</li>
<li>Confirmatory study target population selection is based on:
<ul>
<li>Strong statistical significance in a large subgroup of 114 patients</li>
<li>Subgroup analysis was pre-defined in the statistical analysis plan (SAP)</li>
<li>Strong biological rationale for the results based on Multikine's mechanism of action (MOA)</li>
</ul>
</li>
</ul>
CEL-SCI Corporation (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today highlights strong biological rationale for the use of Multikine in the confirmatory registration head and neck cancer study. This study of 212 newly diagnosed locally advanced, resectable head and neck cancer patients was given the go-ahead as a confirmatory registration study by FDA and will focus on those patients who showed a 73% survival with Multikine vs. a 45% for the control patients not treated with Multikine in the prior Phase 3 study.

Biotech

General

CEL-SCI Announced Multikine Demonstrates Tumor Regression Pre-Surgery In 3 Weeks; FDA Approves 212-Person Study With 73% Survival Rate Vs. 45% Control In Head And Neck Cancer

<a href="https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_12092024_CVM_Vandermosten.pdf" title="https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_12092024_CVM_Vandermosten.pdf">https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_12092024_CVM_Vandermosten.pdf</a>

Analyst Ratings

Watching CEL-SCI; Zacks Small-Cap Research Gives Stock $7 Price Valuation

CEL-SCI And U.S. FDA Approve Use Of PD-L1 Biomarker To Select Head And Neck Cancer Patients For Multikine Registration Study, Targeting Low PD-L1 Expression Patients With 5-Year Survival Rates Of 73%; Study Set To Begin Q1 2025

<ul>
<li>Oncologic Drugs Advisory Committee (ODAC) determines risks outweigh benefits in some cancers for frontline immune checkpoint inhibitors, including blockbuster drugs such as Keytruda and Opdivo, in patients with low PD-L1 expression</li>
<li>Multikine has shown survival benefit and favorable safety profile in a randomized controlled Phase 3 study of treatment naïve resectable locally advanced head and neck cancer patients with low PD-L1 expression</li>
<li>Multikine has potential as a combination drug with current checkpoint inhibitors such as Keytruda which is projected to be the top selling drug in the world with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.statista.com%2Fstatistics%2F973523%2Ftop-drugs-by-year-on-year-sales-increase%2F%23%3A%7E%3Atext%3DKeytruda%2520is%2520projected%2520to%2520be%2Cthan%252027%2520billion%2520U.S.%2520dollars.&amp;esheet=54139913&amp;newsitemid=20241021000924&amp;lan=en-US&amp;anchor=%2427+billion&amp;index=1&amp;md5=df83c0b582408bd76ecc1c7fee8d4c20">$27 billion</a> in 2024 sales</li>
<li>To the Company's knowledge, Multikine is the only neoadjuvant immunotherapy that has shown overall survival benefit in the low and negative PD-L1 head and neck cancer population</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54139913&amp;newsitemid=20241021000924&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=2&amp;md5=68ef23ce754be1ace196803245ed0a4a">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today announced the potential positive impact on the clinical development of its immunotherapy Multikine&#xAE; (Leukocyte Interleukin, Injection)&#x2A; resulting from a recent U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fadvisory-committees%2Fadvisory-committee-calendar%2Fseptember-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024&amp;esheet=54139913&amp;newsitemid=20241021000924&amp;lan=en-US&amp;anchor=meeting&amp;index=3&amp;md5=ae1bd361b36091a7bf7484e1dbf4a939">meeting</a>, a public forum.
FDA advisory committees provide independent expert advice to the FDA on the safety and effectiveness of new and marketed drugs and help the agency make sound and informed decisions. Advisory committees make non-binding recommendations to the FDA, which generally follows the recommendations but is not legally bound to do so.
The September 27, 2024 ODAC meeting evaluated the use of checkpoint inhibitors on patients with various cancers. PD-L1 is the biomarker most often used for patient selection for checkpoint inhibitors, the most successful class of cancer drugs including Keytruda and Opdivo. The FDA sought the ODAC's opinion on the following:
<ul>
<li>adequacy of PD-L1 expression as a predictive biomarker for patient selection in this patient population</li>
<li>differing risk-benefit assessments in different subpopulations defined by PD-L1 expression</li>
<li>adequacy of the cumulative data to restrict the approvals of immune checkpoint inhibitors based on PD-L1 expression</li>
</ul>
Following a thorough analysis of peer-reviewed published data, the panel of experts on the ODAC voted 10-2 and 11–1 against the risk-benefit profile for PD-L1 inhibitors in various cancers in two separate votes. Most ODAC members expressed concerns about the lack of benefit demonstrated for patients with low PD-L1 expression, while some members pointed to evidence that the use of the immune checkpoint inhibitors may add unnecessary toxicities for patients while also increasing financial burdens on patients.
Checkpoint inhibitors were an estimated $48 billion global market in 2023, with PD-L1 inhibitors representing 73% of the market. Current labeling for approved checkpoint inhibitors in the indications evaluated by the FDA's ODAC include broad approvals for all patients, regardless of PD-L1 expression.

CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A Randomized Controlled Phase 3 Study Of Treatment Naïve Resectable Locally Advanced Head And Neck Cancer Patients With Low PD-L1 Expression

Contracts

CEL-SCI Reveals Renewed Collaboration With Ergomed Clinical Research For Its Upcoming FDA Confirmatory Registration Study Of Multikine In Head And Neck Cancer

<ul>
<li>5-year survival rate of 82.6% and 73% reduction in overall risk of death (hazard ratio of 0.27) are the strongest Multikine efficacy results reported to date, reflecting results in patients who met the CEL-SCI confirmatory Registration Study target population criteria and were deemed at low risk for recurrence, therefore not recommended per NCCN guidelines to receive chemotherapy post-surgery</li>
<li>Data provide further evidence that the selection criteria for CEL-SCI's upcoming confirmatory Registration Study may yield improved clinical outcomes</li>
<li>Future advances in diagnostic technologies that improve patient selection, such as PET scans (which will be used in the confirmatory study), may further optimize patient selection and Multikine's already strong efficacy results from the current 5-year Overall Survival at 73% up into the 82% range</li>
<li>Clear unmet need: the 5-year survival rate remains below 50% in locally advanced resectable head and neck cancer patients who receive standard of care only</li>
</ul>

Health Care

CEL-SCI Reported New Data From Its Concluded Phase 3 Study Of Multikine (Leukocyte Interleukin, Injection) Presented At The European Society For Medical Oncology, Showing An Increased 5-year Survival Rate To 82.6% In Locally Advanced Resectable Head & Neck Cancer Patients

Events

CEL-SCI To Present Data for Multikine Head & Neck Cancer Immunotherapy At ESMO 2024 Congress

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fcel-sci.com%2F&amp;esheet=54117012&amp;newsitemid=20240904760257&amp;lan=en-US&amp;anchor=CEL-SCI+Corporation&amp;index=1&amp;md5=bf2ea8e6dbdf9278cbb1ddd2f71b7426">CEL-SCI Corporation</a> (NYSE:<a href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) today reported it has received a decision letter from the United Kingdom's Healthcare Products Regulatory Agency (MHRA) granting Multikine (Leukocyte Interleukin, Injection)&#x2A; a product specific waiver for the treatment of head and neck cancer in a pediatric population of people up to 18 years of age. As a result, CEL-SCI will not be required to evaluate Multikine in a pediatric population as part of license and marketing clearance review in the UK.

Global

The UK's MHRA Grants CEL-SCI's Multikine A Product Specific Waiver For The Treatment Of Head And Neck Cancer In A Pediatric Population Of People Up To 18 Years Of Age

CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 27.27 percent.

Earnings Misses

CEL-SCI Q3 2024 Adj EPS $(0.14) Misses $(0.11) Estimate

Shares of Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SAIA/earnings">second-quarter financial results</a>.
Saia reported quarterly earnings of $3.83 per share which missed the analyst consensus estimate of $4.00 per share. The company reported quarterly sales of $823.24 million which missed the analyst consensus estimate of $826.55 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Saia shares dipped 18.6% to $398.01 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 117.4% to $0.4639 after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares jumped 101.3% to $6.67 after the company filed a request for the withdrawal of its registration statement on a Form S-1.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 53% to $13.94.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares gained 46.2% to $10.83 after the company beat second-quarter earnings estimates.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) shares climbed 43.3% to $8.84. Carbon Revolution said it will supply the carbon fiber wheels available on the just-revealed Chevrolet Corvette ZR1.</li>
<li>Everi Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) rose 41.1% to $12.93 after it entered an agreement to be acquired by funds managed by Apollo affiliates for $14.25 per share in cash.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 37% to $4.45.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) jumped 36.6% to $8.66 on better-than-expected second-quarter earnings and raising FY24 outlook.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 35% to $0.9043.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) rose 28% to $1.55 after the company announced results from a bias analysis conducted for its concluded Phase 3 study of Multikine. Multikine cut the 5-year risk of death by half compared to control in its target population.</li>
<li>AudioEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) rose 25% to $24.52 following second-quarter results.</li>
<li>Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) gained 24.4% to $1.1760. Pineapple Financial CSO Christa Lillian Mitchell bought a total of 2,000 shares at an average price of $0.88.</li>
<li>Douglas Elliman Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) climbed 23% to $1.66.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) rose 19% to $6.71.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) rose 17.6% to $65.16.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) jumped 17% to $368.65 after the company reported better-than-expected second-quarter financial results.</li>
<li>Mohawk Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) gained 16.5% to $156.70 following mixed second-quarter earnings.</li>
<li>Karooooo Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) gained 16% to $33.40. Karooooo announced termination of secondary public offering of ordinary shares due to market conditions.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) climbed 15% to $118.99 after better-than-expected second-quarter financial results and FY24 EPS outlook raise.</li>
<li>International Game Technology PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) gained 13.4% to $22.86 after the company entered an agreement for its Gaming &amp; Digital business to be acquired by funds managed by affiliates of Apollo.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) rose 12.1% to $1.76.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) rose 11% to $15.06.</li>
<li>Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) surged 11% to $25.32 after the company reported better-than-expected second-quarter earnings results.</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) gained 10.7% to $246.86 after the company reported better-than-expected second-quarter earnings results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares gained 10.4% to $0.0415 after falling over 17% on Thursday.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) rose 9% to $20.58. Viasat announced new reporting segment structure.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares gained 8.7% to $914.71 as the company reported better-than-expected results for the first quarter. The company said it still expects net sales to increase approximately 10% year-over-year in fiscal year 2025 to $4.7 billion.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) climbed 7.6% to $48.69 following strong second-quarter earnings and increased 2024 guidance.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) climbed 7.6% to $72.55 following better-than-expected second-quarter financial results and increased 2024 guidance.</li>
<li>Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) rose 7.4% to $25.98 after the company reported better-than-expected quarterly earnings results. Also, multiple firms raised their respective price targets on its stock.</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) gained 6.8% to $319.30 after the company reported better-than-expected quarterly revenue results.</li>
<li>Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) shares gained 4.7% to $47.26 following better-than-expected quarterly results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NovaBay Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) shares dipped 59.6% to $0.7830 after the company reported pricing of $3.5 million underwritten public offering.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) fell 46.9% to $0.2603.</li>
<li>Nature&#8217;s Miracle Holding Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) fell 46.4% to $0.2099 after the company announced pricing of $1.2 million public offering.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 40.7% to $63.97 after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) fell 29.6% to $1.3150. Predictive Oncology announced exercise of warrants for $1.26 million gross proceeds.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) declined 29.2% to $1.5006 as the company reported top-line data from its Phase 1a Alzheimer&#8217;s trial and announced up to $122.7 million private placement financing.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) dipped 26.1% to $1.53</li>
<li>Grom Social Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROM#NASDAQ">GROM</a>) fell 23.8% to $0.2751.</li>
<li>Ocean Power Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) shares declined 23.2% to $0.3188 after reporting fourth-quarter results.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) fell 20.2% to $1.30.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) declined 20.1% to $1.6299.</li>
<li>Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares fell 18.9% to $8.27 after the company reported worse-than-expected second-quarter financial results.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) declined 17.6% to $1.24.</li>
<li>Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>) shares dipped 13.4% to $1.1250 after the company announced a proposed public offering of common shares.</li>
<li>BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) fell 12.6% to $32.53 following quarterly results.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) declined 11.8% to $135.36 following a first-quarter earnings miss and soft EPS guidance.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) shares fell 11.2% to $4.40 after gaining 3% on Thursday.</li>
<li>Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) fell 9.1% to $25.67.</li>
<li>World Acceptance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRLD#NASDAQ">WRLD</a>) dipped 7.8% to $134.62 following weak quarterly sales.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) fell 7.4% to $25.61.</li>
<li>Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) shares declined 7.2% to $44.56 following a second-quarter earnings miss.</li>
<li>Carter&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares fell 6.6% to $55.87 following weak quarterly sales.</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) declined 6.3% to $213.01 after the European Medicines Agency adopted a negative opinion on the Marketing Authorization Approval for lecanemab.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares fell 6% to $38.18. Tandem Diabetes Care will release its second quarter results after the closing bell on Thursday, Aug. 1.</li>
<li>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) declined 4.6% to $232.05 following second-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39984491/nvidia-lockheed-martin-and-2-other-stocks-insiders-are-selling">Nvidia, Lockheed Martin And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

AEYE

ATUS

AVGR

AVTR

BIIB

BJRI

CHTR

CMAX

COLB

COUR

CREV

DECK

DOUG

DXCM

EVRI

FWRD

GROM

KARO

KITT

LBRDA

NMHI

Next Technology Holding Inc. - Ordinary Shares

NXTT

OPTT

PAPL

POAI

PSIG

SAIA

SDST

SGMO

SLNA

TANH

TARS

TNDM

TWOU

UCTT

VSAT

WINT

WRLD

ZYXI

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session

CEL-SCI files to sell 1M shares of common stock for holders

CEL-SCI (CVM) announced that in a recent meeting the FDA concurred with the company's approach to patient selection using low PD-L1 tumor expressio...

CEL-SCI, FDA agree on patient selection approach for Multikine study

CEL-SCI, FDA agree on Phase 3 trial design for cancer drug

Stock Picks From Seeking Alpha's October 2024 New Analysts

CEL-SCI (CVM) highlighted biological rationale for the use of Multikine in the confirmatory registration head and neck cancer study. This study of ...

CEL-SCI provides rationale for use of Multikine in head, neck cancer study

CEL-SCI announces proposed public offering of common stock

CEL-SCI (CVM) announced that it intends to offer to sell shares of its common stock in a best efforts public offering. The company intends to use t...

CEL-SCI announces common stock offering, no amount given

CEL-SCI prices $5 million offering

CEL-SCI (CVM) announced the pricing of a best-efforts public offering of 16,130,000 shares of its common stock. Each share of common stock is being...

CEL-SCI prices $5M public offering at 31c per share

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Comments

CEL-SCI

CEL-SCI (CVM) 옵션

CEL-SCI (AMEX:CVM) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌